BMJ Open Guidelines: is bigger better?

A review of SIGN guidelines

A Gordon Baird, James R Lawrence

To cite: Baird AG, Lawrence JR. Guidelines: is bigger better? A review of SIGN guidelines. *BMJ Open* 2014;**4**:e004278. doi:10.1136/bmjopen-2013-004278

► Prepublication history and additional material for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2013-004278>).

Received 17 October 2013
Revised 13 January 2014
Accepted 14 January 2014

ABSTRACT

Objectives: To quantify and analyse the quality of evidence that is presented in national guidelines.

Setting: Levels of evidence used in all the current valid recommendations in the Scottish Intercollegiate Guideline Network (SIGN) guidelines were reviewed and statistically analysed.

Outcome measures: The proportion of level D evidence used in each guideline and a statistical analysis.

Method: Data were collected from published guidelines available online to the public. SIGN methodology entails a professional group selected by a national organisation to develop each of these guidelines. Statistical analysis of the relationship between the number of guideline recommendations and the quality of evidence used in its recommendations was performed.

Result: The proportion of level D evidence increases with the number of recommendations made. This correlation is significant with Kendall's $\tau=0.22$ (approximate 95% CI 0.008 to 0.45), $p=0.04$; and Spearman $\rho=0.22$ (approximate 95% CI 0.02 to 0.57), $p=0.04$.

Conclusions: Practice guidelines should be brief and based on scientific evidence. Paradoxically the longest guidelines have the highest proportion of recommendations based on the lowest level of evidence. Guideline developers should be more aware of the need for brevity and a stricter application of evidence-based principles could achieve this. The findings support calls for a review of how evidence is used and presented in guidelines.

INTRODUCTION

The Scottish Intercollegiate Guidelines Network (SIGN) was founded in 1993. It is a national body, professionally led and publicly funded. SIGN's founding principles proposed direct links between evidence and recommendations, offering a brief and succinct quick-reference guide for clinicians.¹ Guidelines anticipated presenting brief, evidence-based clinical advice. They have developed into long and authoritative texts used by managers and politicians to inform policy. A formal arrangement between SIGN and the National Institute of Care Excellence (NICE) has existed from 2003. Both have

Strengths and limitations of this study

- This is the first objective evidence of inconsistencies in approach by a national guideline developer.
- This supports commentator suggestion that even without good evidence a group will prefer consensus.
- Adds to the current debate about how guidelines might be developed in the future.
- The study is limited to only one set of national guidelines, that is, the Scottish Intercollegiate Guideline Network (SIGN).
- Reasons for the differences in quality of evidence preferred by the guideline development groups are unclear.

responsibility to consider cost-effectiveness and input to the Quality and Outcomes Framework (QOF).

The WHO recognises that current grades of recommendation (box 1) may be ambiguous² and encourages guideline developers to use a system which includes a category 'Use only in the context of research' where doubt exists.

Guideline developers have conflict of interest policies reported as challenging to apply. Where doubt exists, groups of specialists may feel consensus more defensible than acknowledging uncertainty.³

Even with the best evidence, concerns are expressed about the relevance of guidelines in treating patients with multiple morbidities,⁴ and the emergence of the phenomenon of reversal,^{5 6} where established practice, sometimes evidence based, is shown to be suboptimal or harmful. This study looks at the quality of evidence used for SIGN guidelines, and describes a significant trend for some groups to emphasise poorly evidenced recommendations.

METHODS

SIGN guidelines were accessed online in September 2013. SIGN guidelines were chosen because they are internationally

CrossMark

Research and Development Support Unit, Dumfries and Galloway Royal Infirmary, Dumfries, Scotland, UK

Correspondence to

Dr A Gordon Baird;
gordon.baird@me.com

Box 1 Grades of recommendation

- A. At least one meta-analysis, systematic review, or randomized controlled trial (RCT) rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results
- B. A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 1++ or 1+
- C. A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 2++
- D. Evidence level 3 or 4; or
Extrapolated evidence from studies rated as 2+

respected, the authors were familiar with their format and they contribute to national government policy. Guidelines that were 'Current' and 'Current 3–7 years, some recommendations, may be out of date.', were included. Those that had been 'Withdrawn', 'Recommendations being updated', 'Need for update being considered' and those with no recommendations were excluded.

SIGN guideline 50 clearly describes an established process for developing guidelines.⁷ It explains how the process is planned, how it is implemented and by whom. This process is independent of this study, but is stated to be an objective process. SIGN guidelines have four grades of recommendation outlined in box 1. Table 1 describes the level of evidence SIGN uses to support the recommendation grading. SIGN guideline development groups vary in size depending on the scope of the topic under consideration, but generally comprise between 15 and 25 members. SIGN states they are aware of the

many psychosocial factors, including the problems of overcoming professional hierarchies that can affect small group processes.

Three investigators (JRL, AGB and ABB) independently enumerated the level of evidence used by each guideline. They discounted any duplication implicit in text-embedded key recommendations and also implementation recommendations. There were no discrepancies. A statistical analysis of the correlation between the proportion of level D evidence and the total number of recommendations was performed for the 42 guidelines.

RESULTS

The 42 guidelines consisted of 2559 pages (including references), ranging from 26 to 161 (median 59.5) pages. The longest guideline, number 116 was 61 pages longer than the next largest. The number of recommendations per page ranged from 0.2 to 1.8 (median 0.7). The number of recommendations per guideline is presented in table 2.

Of the 1999 recommendations, 480 (24%) were level A, 491 (24.6%) were level B, 318 (15.9%) level C and 710 (35.5%) level D. Thus 51.4% were poorly evidenced (C and D) and over a third (D) depend almost entirely on 'expert opinion'. The number of level A recommendations per guideline ranged 0–57 (median 9), level B 2–62 (median 8.5), level C ranged 0–26 (median 6) and level D ranged 0–60 (median 14.5). Four guidelines had no level A evidence.

The proportion of level D evidence increases with the number of recommendations made. This correlation is significant with Kendall's $\tau=0.22$ (approximate 95% CI 0.008 to 0.45), $p=0.04$; and Spearman $\rho=0.22$ (approximate 95% CI 0.02 to 0.57), $p=0.04$.

DISCUSSION

This study reveals that expert groups who produce long guidelines rely on poor evidence more heavily than others. While this study only looks at SIGN, this study highlights a problem that has escaped national guideline developers, a wide range of professionals and the public to whom these guidelines are applied. National guidelines are useful and important and there is a debate about how evidence is best presented. Guidelines define standards of care, help busy clinicians and allow managers and politicians to develop governance. An American study (using 3 not 4 levels of evidence) similarly found that 48% were 'based on expert opinion, case studies or standards of care';⁸ we show comparable results for current SIGN guidelines. Where patients are involved in clinical decisions, honestly declaring uncertainty has merit. In the absence of good scientific evidence, recommending a course of action without understanding the circumstances of the individual to whom it is applied seems both risky and, assuming a right to patient choice, unwarranted. Other guidelines that use high levels of poor evidence should evaluate the

Table 1 Levels of evidence

1++	High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
1+	Well conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias
1–	Meta-analyses, systematic reviews, or RCTs with a high risk of bias
2++	High quality systematic reviews of case-control or cohort studies
2+	High quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
2–	Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
3	Non-analytic studies eg, case reports and case series
4	Expert opinion

RCTs, randomised controlled trials.

Table 2 The number of recommendations per guideline

Number	Number	Name	Pages	A	B	C	D	Total	Percentage of D
133	133	Management of hepatitis C	57	20	24	7	52	103	50.5
132	132	Long-term follow-up of survivors of childhood cancer	62	0	7	9	14	30	46.7
131	131	Management of schizophrenia	64	10	19	3	15	47	31.9
130	130	Brain injury rehabilitation in adults	68	0	14	7	8	29	27.6
129	129	Antithrombotics: indication and management	68	25	11	6	19	61	31.1
127	127	Management of perinatal mood disorders	47	0	5	6	15	26	57.7
126	126	Diagnosis and management of colorectal cancer	56	11	19	15	29	74	39.2
125	125	Management of atopic eczema in primary care	34	3	5	3	2	13	15.4
124	124	Management of adult testicular germ cell tumours	63	6	6	9	21	42	50.0
123	123	Management of early rheumatoid arthritis	27	3	7	2	0	12	0.0
122	122	Prevention and management of venous thromboembolism	88	26	15	14	55	110	50.0
121	121	Diagnosis and management of psoriasis and psoriatic arthritis in adults	65	11	16	6	26	59	44.1
120	120	Management of chronic venous leg ulcers	46	5	3	4	7	19	36.8
119	119	Management of patients with stroke: identification and management of dysphagia	42	0	6	4	20	30	66.7
118	118	Management of patients with stroke: rehabilitation, prevention and management of complications, and discharge planning	101	21	29	7	21	78	26.9
117	117	Management of sore throat and indications for tonsillectomy	37	9	3	4	4	20	20.0
116	116	Management of diabetes	161	57	62	23	16	158	10.1
115	115	Management of obesity	87	6	11	7	11	35	31.4
114	114	Non-pharmaceutical management of depression	37	5	4	0	0	9	0.0
113	113	Diagnosis and pharmacological management of Parkinson's disease	61	12	6	6	4	28	14.3
112	112	Management of attention deficit and hyperkinetic disorders in children and young people	45	6	4	3	4	17	23.5
111	111	Management of hip fracture in old people	49	10	9	8	14	41	34.1
110	110	Early management of patients with a head injury	76	1	7	6	17	31	54.8
109	109	Management of genital Chlamydia trachomatis infection	40	3	6	9	29	47	61.7
108	108	Management of patients with stroke or TIA: assessment, investigation, immediate management and secondary prevention	100	42	27	18	14	101	13.9
107	107	Diagnosis and management of headache in adults	81	17	16	9	34	76	44.7
106	106	Control of pain in adults with cancer	71	5	7	3	19	34	55.9
105	105	Management of acute upper and lower gastrointestinal bleeding	57	14	5	2	15	36	41.7
103	103	Diagnosis and management of chronic kidney disease	50	9	6	4	3	22	13.6
102	102	Management of invasive meningococcal disease in children and young people	46	1	4	6	26	37	70.3
99	99	Management of cervical cancer	73	1	13	19	29	62	46.8
97	97	Risk estimation and the prevention of cardiovascular disease	72	16	12	2	4	34	11.8
96	96	Management of stable angina	59	13	10	3	11	37	29.7
95	95	Management of chronic heart failure	55	9	12	1	1	23	4.3
94	94	Cardiac arrhythmias and coronary heart disease	42	22	11	13	23	69	33.3
93	93	Acute coronary syndromes	60	11	14	9	8	42	19.0

Continued

Table 2 Continued

Number	Number	Name	Pages	A	B	C	D	Total	Percentage of D
91	91	Bronchiolitis in children	42	4	3	6	14	27	51.9
90	90	Diagnosis and management of head and neck cancer	92	42	8	26	60	136	44.1
89	89	Diagnosis and management of peripheral arterial disease	37	11	2	0	4	17	23.5
88	88	Management of suspected bacterial urinary tract infection in adults	45	8	10	2	10	30	33.3
87	87	Management of oesophageal and gastric cancer	70	3	26	23	28	80	35.0
61	61	Investigation of postmenopausal bleeding	26	2	7	4	4	17	23.5
		Total	2559	480	491	318	710	1999	

TIA, transient ischaemic attack.

proportion of poorly evidenced recommendations and seek explanations for such trends.

This study did not examine why longer guidelines use poorer evidence. Groups of experts, indulging in 'group think' may view their own opinion as more authoritative than science can support.⁹ It has been postulated that there is security in "just doing what everyone else is doing—even if what everyone else is doing isn't very good."³ Reliance on expert opinion has a poor track record. Blinded by certainty, expert groups defining established practice have, in the past, perpetuated radical mastectomy instead of conservative surgery, class 1C antiarrhythmics,¹⁰ pulmonary artery catheters in heart failure,¹¹ electronic fetal monitoring in low-risk pregnancies: even then practice can take a decade to reverse.¹²

Even good evidence is subject to the phenomenon of reversal where new evidence contradicts current practice. Reversal can affect around 13–16% of publications.^{5 6} This may partly explain why the implementation of even the most soundly evidence based national guidelines fails to improve outcome.^{13–15} There is potential harm^{16 17} from guidelines in real clinical settings, for example, increasing radiation dose without benefit¹⁸ or increased risks of anticoagulation.¹⁹

SIGN 116 (diabetes), is a notable outlier. It is more than 50% larger than the next largest, 2.5 times longer than the average and yet uses the fourth lowest level D recommendations. There are a number of hypotheses why this group reports differently. SIGN guidelines inform QOF policy. Diabetes is the largest clinical UK QOF indicator and is associated with substantial payment incentives. The need for objective evaluation of performance drives a use of surrogate outcomes without appropriate clinical endpoints.²⁰ Diabetes guidelines have suffered several noteworthy reversals. Examples include the recommendation of glycosylated haemoglobin reduction resulting in increased use of rosiglitazone (still mentioned in the current document) both associated with harm including mortality.^{21 22} Aspirin

recommendations have also been changed from previous guidelines. Is it possible that the repeated use of surrogate outcomes arises from group dynamics driven by a powerful external agenda?

Many doctors whose expertise cross several guidelines^{23 24} express concerns about guideline development groups. The inappropriate exclusion of disease groups from general population data is common. Smoking cessation advice is applicable to the general population almost without exception, yet the evidence to stop smoking was graded as B on 3 occasions and level C and D once each. Interpreting evidence inconsistently in this way may imply group dysfunction. Differently constituted groups, or greater oversight might avoid problems.

In 1993, SIGN guidelines stated intention was to be evidence based, brief and succinct. Brevity increases value as a quick reference guide. Removing or reducing poorly evidenced recommendations would reduce size by more than a third overall and in some up to two-thirds. The two volumes Oxford Textbook of Primary Medical Care (2005) is a relatively brief 1420 pages, more than a 1000 less than the 2559 pages of guidelines. Evidence-based medicine is described as "the use of mathematical estimates of the risk of benefit and harm, derived from high-quality research on population samples, to inform clinical decision-making in the diagnosis, investigation or management of individual patients."²⁵ Guidelines relevance to daily practice, the reliability of evidence and whether the application of evidence will improve outcomes are important questions.

These results may reflect how professional groups deal with uncertainty. If so, this is not good for individual patients faced with the same uncertainties (whether aware of it or not), nor is it good for scientists who actively seek unanswered questions by challenging established practice, an area in which medicine has a poor record from Semmelweis to the present day.

The finding of a significant increase of level D recommendations in larger guidelines has not happened by

chance. A wider debate about how guideline groups can create greater clarity about the reliability of evidence used is needed.²⁶ Reducing the use of poorly evidenced recommendations has potential to create a shorter, more reliable and usable clinical support. The GRADE working group was formed in 2000.²⁷ SIGN moved to a new grading system in 2001²⁸ and from 2013 a new system based on GRADE principles. Whether these changes will resolve the challenges that underpin the inconsistencies we have outlined remains to be seen.

Acknowledgements The authors would like to thank Heather Barrington, Statistical Adviser; Bridget Bird, Administrative Assistant; Research and Development Support Unit, Dumfries and Galloway, and Anne B Baird (ABB), Sandhead Surgery, Sandhead, Wigtownshire.

Contributors AGB and JRL were involved in revising the raw data and agreed on a statistical approach to discover whether the trend was significant or not, and were also involved in writing and researching the evidence.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Extra data can be accessed via the Dryad data repository at <http://datadryad.org/> with the doi:10.5061/dryad.r2fh0.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

1. Harbour R, Lowe G, Twaddle S. Scottish Intercollegiate Guidelines Network; the first 15 years (1993–2008). *J R Coll Physicians Edinb* 2011;41:163–8.
2. de Joncheere K, Hill S, Klazinga N, *et al*. The Clinical Guideline Programme of the National Institute for Health and Clinical Excellence (NICE). A review by the World Health Organization May 2006.
3. Lenzer J. Why we can't trust clinical guidelines. *BMJ* 2013;346:f3830.
4. Aylett V. Do geriatricians need guidelines? *BMJ* 2010;341:c5340.
5. Prasad V, Cifu A, Ioannidis JP. Reversals of established medical practices: evidence to abandon ship. *JAMA* 2012;307:37–8.
6. Prasad V, Gall V, Cifu A. The frequency of medical reversal. *Arch Intern Med* 2011;171:1675–6.
7. SIGN 50. *A guideline developer's handbook*. <http://www.sign.ac.uk/pdf/sign50.pdf>
8. Tricoci P, Allen JM, Kramer JM, *et al*. Scientific evidence underlying the ACC/AHA clinical practice guidelines. *JAMA* 2009;301:831–41.
9. Raine R, Sanderson C, Black N. Developing clinical guidelines: a challenge to current methods. *BMJ* 2005;331:631–3.
10. Echt DS, Liebson PR, Mitchell LB, *et al*. Mortality and morbidity in patients receiving encainide, flecainide, or placebo—the Cardiac Arrhythmia Suppression Trial. *N Engl J Med* 1991;324:781–8.
11. Binanay C, Califf RM, Hasselblad V, *et al*. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. *JAMA* 2005;294:1625–33.
12. Tatsioni A, Bonitsis NG, Ioannidis JA. Persistence of contradicted claims in the literature. *JAMA* 2007;298:2517–26.
13. Anderson JE, McKenzie C, Singh N, *et al*. Compliance with the 62 day target does not improve long-term survival. Association of Coloproctology of Great Britain and Ireland Annual Meeting, 2012, Dublin, Ireland.
14. Kerr J, Smith R, Gray S, *et al*. An audit of clinical practice in the management of head injured patients following the introduction of the Scottish Intercollegiate Guidelines Network (SIGN) recommendations. *Emerg Med J* 2005;22:850–4.
15. Caplan LR. How well does “evidence-based” medicine help neurologists care for individual patients? *Rev Neurol Dis* 2007;4:75–84.
16. Hutchison G. Guidelines can harm patients too. *BMJ* (Clinical research ed.) 2012;344:e2685.
17. Woolf SH, Grol R, Hutchinson A, *et al*. Clinical guidelines. Potential benefits, limitations, and harms of clinical guidelines. *BMJ* 1999;318:527–30.
18. Miller L, Kidd A. Are sign guidelines key in the decision to CT? Post-head injury CT scanning within a paediatric population. Academic Emergency Medicine. Conference: 14th International Conference on Emergency Medicine, ICEM 2012 Dublin Ireland. Conference Publication: 19, pp. 776, 2012. Date of Publication: June 2012.
19. Thomson R, Eccles M, Wood R, *et al*. A cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke prevention. *Med Decis Making* 2007;27:438–47.
20. Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. *BMJ* 2011;343:d7995.
21. Cohen D. Rosiglitazone: what went wrong? *BMJ* 2010;341:c4848.
22. Gerstein HC, Miller ME, Byington RP, *et al*. Effects of intensive glucose lowering in type 2 diabetes. Action to Control Cardiovascular Risk in Diabetes Study Group. *N Engl J Med* 2008;358:2545–59.
23. Rashidian A, Eccles MP, Russell I. Falling on stony ground? A qualitative study of implementation of clinical guidelines' prescribing recommendations in primary care. *Health Policy* 2008;85:148–61.
24. Guy S, Wardlaw JM. Who writes guidelines, and who should? *Clin Radiol* 2002;57:891–7.
25. Greenhalgh T. *How to read a paper: the basics of evidence-based medicine*. Wiley-Blackwell, 4th edn. 2010:1.
26. Zuiderent-Jerak T, Forland F, Macbeth F. Guidelines should reflect all knowledge, not just trials. *BMJ* 2012;345:e6702.
27. GRADE working group. Grading quality of evidence and strength of recommendations. *BMJ* 2004;328:1490.
28. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. *BMJ* 2001;323:334–6.